Recombinant Adenoviral Vector Containing Tumor-Specific L-Plastin Promoter Fused to Cytosine Deaminase Gene as a Transcription Unit: Generation and Functional Test

  • Chung, In-Jae (College of Pharmacy, Duksung Women's University) ;
  • Deisseroth, Albert-B. (Sidney Kimmel Cancer Center)
  • Published : 2004.06.01

Abstract

The expression of therapeutic transgenes in recombinant adenoviral vectors is a major cause of toxicity in dividing cancer cells as well as non dividing normal cells. To solve the problem of toxicity to normal cells, we have reported on a recombinant adenoviral vector system (AdLP-) in which the expression of the transgene is directed by the tumor-specific L-plastin promoter (LP) (Chung et al., 1999). The object of this study was to generate a recombinant adenoviral vector system which would generate tumor cell specific expression of cytosine deaminase (CD) gene. We report the construction of a replication-incompetent adenoviral vector in which CD is driven by the L-plastin promoter (AdLPCD). Infection of 293 cells by AdLPCD generated the functional CD protein as measured by HPLC analysis for the conversion of 5-Fluorocy-tosine (5-FC) to 5-Fluorouracil (5-FU). HPLC analysis in conjunction with counting radioactivity for [6-$^3$H]-5FC and [6-$^3$H]-5FU demonstrated vector dose-dependent conversion of 5-FC to 5-FU in AdLPCD infected ovarian cancer cells. The results from present and previous studies(Peng et al., 2001; Akbulut et al., 2003) suggest that the use of the AdLPCD/5-FC system may be of value in the treatment of cancer including microscopic ovarian cancer in the peritoneal cavity.

Keywords

References

  1. Akbulut, H., Zhang, L., Tang, Y, and Deisseroth, A., Cytotoxic effect of replication-competent adenoviral vectors carrying Lplastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon. Cancer Gene Ther., 10(5), 388-395(2003) https://doi.org/10.1038/sj.cgt.7700579
  2. Anderson, L., Kilstrup, M., and Neuhard, J., Pyrimidine, purine and nitrogen conrol of cytosine deaminase synthesis in Escherichia coli K12. Involvement of the glnG and purR genes in the resgulation of codA expression. Arch. Microbiol., 152, 115-118 (1989) https://doi.org/10.1007/BF00456087
  3. Austin, E. A., and Huber, B. E., A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of E. coli cytosine deaminse. Mol. Pharmacol., 43, 380-387(1993)
  4. Cannistra, S. A., Cancerof the ovary. N. Engl. J. Med., 329(21), 1550-1559(1995) https://doi.org/10.1056/NEJM199311183292108
  5. Chung, I., Schwartz, P. E., Crystal, R. G., Pizzorno, G., Leavitt, J., and Deisseroth, A. B., Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancercells but not in normal mesothelial cells. Cancer Gene Ther, 6 (2), 99-106 (1999) https://doi.org/10.1038/sj.cgt.7700017
  6. Glazer, R. I. and Lloyd, L. S., Association of cell lethality with incorporation of 5-fluorouracil and 5-fluoridine into nuclear RNA in human colon carcinoma cells in culture. Mol. Pharmacol., 21, 468-473 (1992)
  7. Graham, F. L., and Prevec, L., Manipulation of adenovirus vectors, Methods in molecularbiology, Vol. 7, p109-128, E. J. Murray, The Human Press Inc., Clifton, NJ. (1991)
  8. Hirschowitz, E. A., Ohwada, A., Pascal, W. R., Russi, T. J., and Crysta, R. G., In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Human Gene Ther., 6(8), 1055-1063 (1995) https://doi.org/10.1089/hum.1995.6.8-1055
  9. Huber, B. E., Austin, E. A., Good, S. S., Knick, V. C., Tibbels, S., and Richards, C. A., In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically codified to express cytosine deaminase. Cancer Res., 53, 4619-4626 (1993)
  10. Kufe, D. W. and Major, P. P., 5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity. J. Biol. Chem., 256, 9802-9805(1991)
  11. Leavitt, J., Discoveryand characterization of two novel huamn cancer-related proteins using two-dimensional gel electrophoresis. Electrophoresis, 15, 345-357(1994) https://doi.org/10.1002/elps.1150150154
  12. Lin, C.-S., Chen, Z. P., Park, T., Ghosh, K., and Leavitt, J., Characterization of the human L-plastin gene promoter in normal and neoplastic cells. J. Biol. Chem., 268(4), 2793-2801 (1993a)
  13. Lin, C.-S., Park, T., Chen, Z. P., and Leavitt, J. L., Human plastin genes.J. Biol. Chem., 268(4), 2781-2792 (1993b)
  14. Miller, N. and Whelan, J., Progress in transcriptionally targeted and regulatable vectors for genetic therapy. Human Gene Ther., 8, 803-815 (1997) https://doi.org/10.1089/hum.1997.8.7-803
  15. Moolten, F. L., Drug sensitivity ('suicide') genes for selective cancer chemotherapy. Cancer Gene Ther., 1, 279-287 (1994)
  16. Peng, X. Y., Won, J. H., Rutherford, T., Fujii, T., Zelterman, D., Pizzorno, G., Sapi, E., Leavitt, J., Kacinski, B., Crystal, R., Schwartz, P., and Deisseroth, A., The use of the L-plastin promoter for adenoviral-mediated , tumor-specific gene expression in ovarian and bladder cancer cell lines. Cancer Res., 61(11),4405-4413 (2001)
  17. Pritchard, D. M., Watson, A. J., Potten, C. S., Jackman, A. L., and Hickman, J. A., Inhibition by uridine but not thymidine fo p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. Proc. Natl. Acad. Sci. U.S.A., 94(5), 1795-1799 (1997) https://doi.org/10.1073/pnas.94.5.1795
  18. Zhang, W. W., Fang, X., Branch, C. D., Mazur, W., French, B. A., and Roth, J. A., Generation and identification of recombinant adenovirus by liposome-mediated transfection and PCR analysis. Biotechnques, 15(5), 868-872 (1993)